St Jude Medical To Sponsor SCD-HeFT Ten-year Follow-up Study
The original SCD-HeFT study has proved the effectiveness of ICD therapy over placebo or Amiodarone (a medication used to treat irregular heartbeats) for a specific population of patients.
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).